351 results about "Antiinflammatory Effect" patented technology

The invention discloses an application of anemoside B4 used as an immunomodulator to drugs for treating acute inflammations. The anti-inflammatory effect of the anemoside B4 is directly produced through inhibition of lymphocyte activation and inflammatory factor secretion. The application of the anemoside B4 used as the immunomodulator to the drugs for treating acute inflammations is disclosed for the first time, and the anemoside B4 belongs to a purely natural preparation, is safe, reliable and free of side effects and has potential development value for the drugs for treating acute inflammations.

The present invention has an object to provide an external dermatological formulation having satisfactory blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing effect, hair nourishing effect, emusifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and / or transdermal absorption-promoting effect with a satisfactory safety and skin feeling; The object is solved by providing an external dermatological formulation comprising a saccharide derivative of α,α-trehalose and one or more members selected from substances having any one of blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing efect, hair nourishing effect, emulsifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and transdermal absorption-promoting effect.

The present invention has an object to provide an external dermatological formulation having satisfactory blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing effect, hair nourishing effect, emusifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and / or transdermal absorption-promoting effect with a satisfactory safety and skin feeling; The object is solved by providing an external dermatological formulation comprising a saccharide derivative of alpha , alpha -trehalose and one or more members selected from substances having any one of blood flow-promoting effect , antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing efect, hair nourishing effect, emulsifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and transdermal absorption-promoting effect.

N-Arylphenylacetamide derivatives represented by the following formula [I]:(wherein R1 is C1-6 alkoxy, etc.; R2 is hydrogen, —(CH2)m—N(R6)(R7) (m is an integer of from 1 to 4; R6 is hydrogen, C1-4 alkyl, etc., R7 is hydrogen, etc.), etc.; R3 is hydrogen, halogen, etc.; R4 is C6-10 alkyl, —Y—R8 (Y is a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc., R8 is aryl, C3-8 cycloalkyl, C6-15 polycycloalkyl, etc.), etc.; R5 is hydrogen, etc.; and X1 is hydrogen), or pharmaceutically acceptable salts thereof or hydrates or solvates of the same, and a pharmaceutical composition containing the same. These compounds are useful as preventives and / or remedies giving no pain at the early stage of administration, which are efficacious in oral administration and have potent analgesic and antiinflammatory effects.

The invention belongs to the field of biological medicines, and particularly discloses a mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and a preparing method for the preparation. The preparation is composed of umbilical cord or placenta mesenchymal stem cells and cytokines, as well as hyaluronate which is used for bearing the umbilical cord or placenta mesenchymal stem cells and cytokines and has the slow-release and anti-inflammatory effects; and the preparation is injected into a part of the endometrium and ovary in a targeted manner to be slowly released and absorbed. The curative effect of repairing the ovary and endometrium can be achieved, functional ovulation can be promoted, the premature ovarian failures can be treated, and the various perimenopausal syndromes can be remitted. Compared with an existing intravenous re-transfusion and intervention path, untoward effects of intravenous transfusion are avoided through the preparation and a using method of the preparation, abdomen and local wounds caused by interventional treatment are avoided, and side effects and hurts caused by treatment to a patient can be effectively prevented, so that the preparation is safer and more effective, is high in practicability and easy to popularize, and has the huge application value.

The invention discloses soothing, repairing and moisturizing face cream and a preparation method thereof. The face cream is mainly prepared by compounding bisabolol, 4-tert-butyl cyclohexanol, a plantsoothing component, a skin conditioner and a moisturizer, wherein the plant soothing component and the bisabolol have instant itching relieving and anti-inflammatory effects; the 4-tert-butyl cyclohexanol can immediately relieve the burning feeling and the pricking feeling, and the skin conditioner can repair the skin; and the moisturizer has moisturizing and moistening effects, and can soften the skin and lock the skin moisture. The face cream is mild, non-irritant, safe, free of toxic and side effects, can effectively moisturize and repair skin and repair couperose skin, and is suitable forbeing used by crowds with partial sensitive skin and more sensitive skin.

The invention relates to the technical field of functional food, and discloses a composite probiotic composition and application thereof. The probiotic composition comprises, by weight, 1-25 parts ofbacterial probiotic, 1-15 parts of yeast probiotic and 20-70 parts of prebiotic. The probiotic composition can be effectively colonized in the oral cavity and the intestine to regulate the micro-ecology of the flora in the oral cavity and the intestine, exert antibacterial and anti-inflammatory effects and improve various oral discomforts and intestine uncomfortable symptoms caused by imbalance ofthe flora. At the same time, the health condition of the oral cavity and the intestine can be improved, and the composition can be used for preparing products for improving, preventing and treating oral or intestine discomforts.

The invention discloses a novel heptacyclic compound (2'S,5'S)-tetrahydropyrazine [1',2':1,6] and bis{2,3,4,9-tetrahydro-1H-pyridine [3,4-b] indole}-1',4'-diketone (THPDTPI for short), a preparation method thereof, and antithrombosis action, anti-inflammatory action, anti-tumor action, free radical scavenging action and P-selectin expression inhibition action thereof. Therefore, the invention discloses application of the THPDTPI in preparing a medicament which takes the P-selectin as a target and simultaneously inhibits thrombosis, inflammation and tumor. Because thrombosis and inflammation are the most popular complications in patients with tumor, the THPDTPI not only can treat tumor, but also can prevent patients with tumor from complicating thrombosis and inflammation. The THPDTPI disclosed by the invention has favorable clinical application prospects.

The claimed invention is composition comprising an organic extract of de-fleshed, purified, isolated olive kernels that contains one or more components that increase absorption of macromolecules such as proteoglycans across cell membranes, that have antioxidant properties, and that have anti-inflammatory effects in tissues.

N-Arylphenylacetamide derivatives represented by the following formula [I]: (wherein R<1 >is C1-6 alkoxy, etc.; R<2 >is hydrogen, -(CH2)m-N(R<6>)(R<7>) (m is an integer of from 1 to 4; R<6 >is hydrogen, C1-4 alkyl, etc., R<7 >is hydrogen, etc.), etc.; R<3 >is hydrogen, halogen, etc.; R<4 >is C6-10 alkyl, -Y-R<8 >(Y is a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc., R<8 >is aryl, C3-8 cycloalkyl, C6-15 polycycloalkyl, etc.), etc.; R<5 >is hydrogen, etc.; and X<1 >is hydrogen), or pharmaceutically acceptable salts thereof or hydrates or solvates of the same, and a pharmaceutical composition containing the same. These compounds are useful as preventives and / or remedies giving no pain at the early stage of administration, which are efficacious in oral administration and have potent analgesic and antiinflammatory effects.

A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful as a safe preventive and / or a remedy for respiratory diseases (for example, asthma, pulmonary injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, adult respiratory distress syndrome, cystic fibrosis, pulmonary hypertension or the like) without causing any systemic effect such as lowering blood pressure. Thus, a safe and useful remedy for respiratory diseases is provided.

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally.A compound represented by the following formula (I):wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, or a benzyloxy group which may be substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group which may be substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C—R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group),or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.

Pharmacological test shows that the externally-used preparation of Cetirizine has ideal allergy resistant and anti-inflammatory action to the rat passive cutaneous anaphylaxis (Rat PCA) model and dimethylbenzene caused mouse otitis model, and also prevents the adverse effect to the central system caused by whole body administration. It is also found in the test, that the externally used preparation of Cetirizine also has very fine inhibitory action to dinitrofluorobenzene caused mouse porphyria hypersensitivity (PTH), the novel pharmacological action of the Cetirizine shows that the Cetirizine external preparation has good therapeutic action to skin inflammations which mainly include porphyria hypersensitivity.

The present invention has an object to provide an external dermatological formulation having satisfactory blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing effect, hair nourishing effect, emusifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and / or transdermal absorption-promoting effect with a satisfactory safety and skin feeling; The object is solved by providing an external dermatological formulation comprising a saccharide derivative of α,α-trehalose and one or more members selected from substances having any one of blood flow-promoting effect, antiinflammatory effect, antibacterial effect, moisturizing effect, whitening effect, UV-absorbing effect, UV-scattering effect, antioxidant effect, hair growing efect, hair nourishing effect, emulsifying effect, astringent effect, wrinkle-reducing effect, cell-activating effect and transdermal absorption-promoting effect.

The invention relates to conjugates of saturated aliphatic chain alcohol, dexamethasone, and Glu-Asp-Gly, preparation, a nano structure, and applications thereof. The invention discloses 6 saturated aliphatic chain alcohol modified dexamethasone-Glu-Asp-Gly conjugates represented by the formula 10 a-f, wherein in the formula the n represents 7, 9, 11, 13, 15, or 17. The invention also discloses a preparation method, a nano structure, immunity inhibition activity, inflammation inhibition activity, and pain relieving activity of the conjugates. The invention also finds that the conjugates do not have any side effect leading to osteoporosis. The researches on the inhibition effect of the conjugates on splenic lymphocyte mitogen proliferation reactions and the survival time after mouse retroauricular cardiac muscle transplant show that the conjugates have an excellent immunity inhibition effect. The researches on the effect of the conjugates on the swelling degree of mouse ears which are inflamed due to xylene show that the conjugates have an excellent anti-inflammation effect. The researches on the effect of the conjugates on mouse heat radiation tail flick time show that the conjugates have an excellent pain-relieving effect. The researches on the effect of the conjugates on the mouse thigh bones show that the conjugates cannot cause osteoporosis. So the conjugates have a wide application prospect in the preparation of immunity inhibition drugs.

The present invention relates to novel topical compositions for treating burns, grazes, erythema, eczema, herpes infection, evulsion, sores and any skin damage leading to sloughing, including at least three components, namely a first barrier gel, a second barrier gel and an active principle having proteolytic activity. The novel compositions have enhanced pain-killing, protective, débrding and anti-inflammatory effects relative to the conventional products used in the art.

The present invention relates to 1-aza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

Medicinal compositions characterized by containing fudosteine and an antipyretic / analgesic. These medicinal compositions are medicinal compositions to be used for common cold, etc. which have improved sputum-removal and antiinflammatory effects.

Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative.

The invention provides a preparation method of a malan straw extract, a malan straw product, a pharmaceutical composition and an application thereof. The preparation method comprises the following steps: selecting a right amount of malan straw, crushing into coarse powder or intermediate powder, extracting 2-3 times by decoction in water or by ethanol / petroleum ether refluxing with 1-2 hours for each time, filtering, merging the filtrates, concentrating, and drying to obtain the malan straw extract. The preparation process of the malan straw extract is simple and practicable, and the obtained extract has obvious anti-inflammatory effect and pain-relieving effect and shows good effects for treating hepatitis, gynecologic inflammation, inflammation of urinary system, pneumonia and nephritis diseases, thereby achieving favorable application prospects.

The invention relates to the technical field of medicines, and particularly relates to cryptotanshinone for preventing and treating pulmonary fibrosis and an application thereof. The cryptotanshinone (I) is quinone diterpene extracted from the root part of salviae miltiorrhizae; the modern pharmacological research shows that the cryptotanshinone has a bacteriostatic effect, an anti-inflammatory effect and a hormone-like pharmacologic effect, and is clinically used for treating myocardial fibrosis, lung acute injury and arthritis, can be used for preventing and / or treating a pulmonary fibrosis disease, can also be used for preparing medicines for reducing body weight of a pulmonary fibrosis rat, a lung coefficient and the content of hydroxyproline in tissue and can be used for preparing the medicines for reducing the content of IL-1beta, IL-6 and TNF-alpha in a bronchoalveolar lavage liquid and the medicines of effecting the pathogeny structure of pulmonary fibrosis tissue of the rat. The formula (I) is as shown in the specification.

The invention relates to a ketoprofen gel and a preparation method thereof. The ketoprofen gel is prepared from the following components: 2-5 % of ketoprofen, 0.5-2 % of matrix material, 2-4 % of a transdermal enhancer, 0.5-5 % of a neutralizer, 0.05-0.2 % of an anti-oxidant, 20-50 % of ethanol and the balance being water. The ketoprofen gel provided by the invention solves problems of stimulation of ketoprofen preparations on gastrointestinal tract in a background technology, is used externally, has advantages of good transdermal effect, quick effect and good analgesic and anti-inflammatory effects, and can play drug effects for a long time.

The invention relates to a preparation method and application of oral microspheres loaded with MSCs-derived exosomes. The preparation method comprises the following steps: (1) preparing an ALG / CST inner core solution; (2) preparing an ALG / CNC outer core solution; (3) separating exosomes derived from mesenchymal stem cells; and (4) preparing microspheres loaded with the MSCs exosomes. In the invention, hydrophobic ALG / CST and hydrophilic ALG / CNC are combined, the ALG / CST is used for wrapping the inter core of the exosomes, the defects of easy acidolysis of ALG, low drug loading of CNC andthe like are overcome, and the exosomes are effectively protected from being damaged by gastric acid and digestive juice. Meanwhile, with the pH-sensitive slow-release targeting property of small intestines, MSCs can be safely transported to the small intestines in an oral mode, damage repair, immunoregulation and anti-inflammatory effects are carried out by means of a small intestine absorption function, and the treatment of RA and other related autoimmune diseases is realized.

The invention discloses a medicine for treating tracheitis and bronchitis and a preparation method thereof. The natural botanical drugs chosen by the invention comprise peucedanum root, white mulberry bark, loquat leaf, bitter apricot seed, ephedra, baikal skullcap root, etc. The medicine of the invention has the efficacies of clearing away the lung-heat to purge heat, resolving phlegm to relieve cough, preventing asthma and sending down abnormally ascending. Tests and studies indicate that the medicine of the invention has obvious anti-infectious effects on the infection of mice caused by staphylococcus aureus and has obvious inhibitory action on ear dwelling caused by xylene and on leg dwelling of rats caused by 1% carrageenin, which indicates that the medicine has obvious anti-inflammatory action; in addition, the medicine of the invention has obvious effects on relieving cough, resolving phlegm and relieving asthma, which can be used for treating tracheitis and bronchitis in clinical practice.

The invention relates to the quality control field of traditional Chinese medicine, in particular to a quality control method of a compound anti-inflammatory and cholagogic preparation and applications thereof. The method comprises the steps of: establishing a standard fingerprint, establishing a fingerprint of a sample and comparing the standard fingerprint with the fingerprint of the sample. The standard fingerprint of the compound anti-inflammatory and cholagogic preparation shows 15 main chromatographic peaks in 225nm and confirms the chemical structures of 8 chromatographic peaks in the 15 main chromatographic peaks. The active ingredients with anti-inflammatory effect of three ingredients comprising andrographolide, rosemarinic acid and nigakinone in the 8 chemical structures are further confirmed. As the supplementation of the method, the three ingredients or the combination of the three ingredients can be indicative ingredients used for carrying content measurement. The method has high repeatability, good stability and simple and convenient operating method, is scientific with evidences and can effectively control the quality of the compound anti-inflammatory and cholagogic preparation.

The invention discloses application of a glutaminase inhibitor in preparation of a medicine for treating psoriasis. In-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, including remarkably reducing the Baker score of skin lesion, effectively reducing the epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing the medicine for treating psoriasis.

A patch for transdermal administration having a sufficiently high transdermal permeation property of a COX-2 inhibitor to exert a superior antiinflammatory effect, the patch for transdermal administration comprising a backing and an adhesive layer which is placed on at least one side of the backing and comprises an adhesive base agent and a drug, wherein the drug is valdecoxib or a pharmaceutically acceptable salt thereof.

The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea / vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.

The invention relates to a medicinal composition for treating canker sore and local infection of body surface and reducing inflammation, a product and application thereof. The medicinal composition comprises aminoglycoside antibiotics, local anaesthetics and glucocorticoids in weight ratio of (0.1-10):(1-10):(0.01-10). Compared with the prior art, the medicinal composition has the advantages that local anaesthetics can alleviate pains of patients in time; antibiotics has the antibiotic effect of treating infection caused by bacteria; and the glucocorticoids has the anti-inflammatory effect of reducing focus hyperemia, reducing permeability of capillary and inhibiting inflammatory cells from transferring to the inflammatory part; and the synergistic action of the three medicaments promotes the healing of canker sore so as to achieve good treatment effect.

The invention belongs to the technical field of atherosclerotic targeted drugs, and discloses a medicine for resisting atherosclerotic inflammation and an anti-inflammatory effect detection method, and the medicine for resisting atherosclerotic inflammation is artesunate. The method for detecting the anti-inflammatory effect of the medicine for resisting atherosclerotic inflammation comprises thefollowing steps: performing an in-vitro experiment of using ox-LDL to induce VSMC phenotype to be converted into inflammatory phenotype cells; performing an in vivo experiment of using ox-LDL to induce VSMC phenotype to be converted into inflammatory phenotype cells. According to the invention, a molecular biology method is adopted, and the artesunate and target protein NLRP3 binding target is comprehensively investigated through a cell model and an animal model for inhibiting ox-LDL from inducing phenotypic transformation of VSMCs inflammatory cells by artesunate; and the anti-inflammatory effect and the molecular mechanism of artesunate in AS vascular inflammatory injury are illustrated by inhibiting the anti-inflammatory effect and the molecular mechanism of ox-LDL induced VSMCs inflammatory cell phenotypic transformation.